Skip to main content
. 2020 Mar 29;22(7):1141–1150. doi: 10.1111/dom.14015

Figure 4.

Figure 4

Effect of empagliflozin versus placebo on major outcomes by TRS‐HFDM category, in patients without HF at baseline. 3P‐MACE, three‐point major adverse cardiovascular events; CI, confidence interval; CV, cardiovascular; HHF, hospitalization for heart failure; TRS‐HFDM, Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes. †Excluding fatal stroke. Cox regression analysis for time to first event in patients treated with ≥1 dose of study drug